Cas 611213-59-3,2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-5-benzothiazolyl]oxy]-N-methyl-

611213-59-3

Post Buying Request

Basic information

Product Name: 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-5-benzothiazolyl]oxy]-N-methyl-
Synonyms:
CAS NO:611213-59-3
Molecular Formula: C20H15BrN4O2S
Molecular Weight: 455.335
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-5-benzothiazolyl]oxy]-N-methyl-(CAS DataBase Reference)
NIST Chemistry Reference: 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-5-benzothiazolyl]oxy]-N-methyl-(611213-59-3)
EPA Substance Registry System: 2-Pyridinecarboxamide, 4-[[2-[(4-bromophenyl)amino]-5-benzothiazolyl]oxy]-N-methyl-(611213-59-3)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 611213-59-3(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

611213-59-3 Suppliers

Recommended suppliers

611213-59-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 611213-59-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,1,2,1 and 3 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 611213-59:
(8*6)+(7*1)+(6*1)+(5*2)+(4*1)+(3*3)+(2*5)+(1*9)=103
103 % 10 = 3
So 611213-59-3 is a valid CAS Registry Number.

611213-59-3Upstream product

220000-87-3 4-chloro-N-methylpicolinamide

611213-59-3Downstream Products

611213-59-3Relevant academic research and scientific papers

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

-

Page 36-37, (2008/06/13)

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 611213-59-3